- Research article
- Open Access
- Open Peer Review
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas
© Lucio-Eterovic et al; licensee BioMed Central Ltd. 2008
- Received: 11 April 2008
- Accepted: 19 August 2008
- Published: 19 August 2008
Glioblastoma is the most lethal primary malignant brain tumor. Although considerable progress has been made in the treatment of this aggressive tumor, the clinical outcome for patients remains poor. Histone deacetylases (HDACs) are recognized as promising targets for cancer treatment. In the past several years, HDAC inhibitors (HDACis) have been used as radiosensitizers in glioblastoma treatment. However, no study has demonstrated the status of global HDAC expression in gliomas and its possible correlation to the use of HDACis. The purpose of this study was to evaluate and compare mRNA and protein levels of class I, II and IV of HDACs in low grade and high grade astrocytomas and normal brain tissue and to correlate the findings with the malignancy in astrocytomas.
Forty-three microdissected patient tumor samples were evaluated. The histopathologic diagnoses were 20 low-grade gliomas (13 grade I and 7 grade II) and 23 high-grade gliomas (5 grade III and 18 glioblastomas). Eleven normal cerebral tissue samples were also analyzed (54 total samples analyzed). mRNA expression of class I, II, and IV HDACs was studied by quantitative real-time polymerase chain reaction and normalized to the housekeeping gene β-glucuronidase. Protein levels were evaluated by western blotting.
We found that mRNA levels of class II and IV HDACs were downregulated in glioblastomas compared to low-grade astrocytomas and normal brain tissue (7 in 8 genes, p < 0.05). The protein levels of class II HDAC9 were also lower in high-grade astrocytomas than in low-grade astrocytomas and normal brain tissue. Additionally, we found that histone H3 (but not histone H4) was more acetylated in glioblastomas than normal brain tissue.
Our study establishes a negative correlation between HDAC gene expression and the glioma grade suggesting that class II and IV HDACs might play an important role in glioma malignancy. Evaluation of histone acetylation levels showed that histone H3 is more acetylated in glioblastomas than normal brain tissue confirming the downregulation of HDAC mRNA in glioblastomas.
- HDAC Inhibitor
- Normal Brain Tissue
- HDAC Expression
- Normal Colorectal Tissue
Gliomas, the most common brain tumor, are currently classified as astrocytic, ependymal, oligodendroglial and choroid plexus tumors. Among astrocytic tumors, glioblastoma (World Health Organization grade IV ) is the most lethal primary malignant brain tumor. Although considerable progress has been made in its treatment, the clinical prognosis associated with this tumor remains poor.
Class II HDACs includes HDAC4, -5, -6, -7, -9a, -9b, and -10, which are homologous to yeast Hda1. These class II enzymes can be found in the nucleus and cytoplasm, suggesting potential extranuclear functions by regulating the acetylation status of nonhistone substrates [9, 10]. HDAC members of class II are abundantly expressed in skeletal muscle, heart, brain, tissues with low levels of mitotic activity [11, 12]. Functionally, Class II HDACs is thought to act as transcriptional corepressors by deacetylating nucleosomal histones. These enzymes do not bind directly to DNA; they are thought to be recruited to distinct regions of the genome by sequence specific DNA binding proteins [13–15].
Class III HDACs is composed of the Sirtuins (SIRT) proteins 1–7, which are homologous to the yeast Sir2 protein and require NAD+ for deacetylase activity in contrast to the zinc-catalyzed mechanism used by class I and II HDACs [16–18].
An additional HDAC expressed by higher eukaryotes is a Zn-dependent HDAC (HDAC11 in mammals). This enzyme is phylogenetically different from both class I and class II enzymes and is therefore classified separately as class IV  reviewed in .
The use of HDAC inhibitors (HDACis) for the treatment of cancer is an area of active investigation. In gliomas, HDACis have been used for the treatment of glioblastoma in combination with radiation therapy and chemotherapy. Some authors have demonstrated that HDACis have a radiosensitizing effect on glioblastoma cells in vitro and in vivo [20–23] and also seem to be associated with inhibition of glioma cell growth by both cell-cycle arrest and apoptosis [24–26]. Despite the widespread use of HDACis, the mechanistic implications remain to be elucidated.
To this date, there are no studies that demonstrate the status of global HDAC gene expression and protein levels in astrocytomas. The purpose of this study was to evaluate and compare mRNA and protein levels of class I, II and IV of HDACs in low grade and high grade astrocytomas and normal brain tissue and to correlate the findings with the malignancy in astrocytomas.
For this study, tumor samples of 43 patients (19 men and 24 women) ranging in age from 1.3 to 79 years (mean age 24.6 years, with a median and a standard deviation of 12.8 ± 22.6 years) were evaluated. The histopathologic diagnoses were 20 low-grade gliomas (13 grade I and 7 grade II) and 23 high-grade gliomas (5 grade III and 18 glioblastomas). In addition, 11 samples of normal cerebral tissue were analyzed. Frozen tumor and normal specimens were microdissected. Diagnoses were based on 2007 World Health Organization criteria .
For tumor microdissection, tumor samples were placed on a cooled platform and immediately positioned on the cutting base of the cryostat under Tissue Tek (Fisher Scientific, Pittsburg, PA). After rapid freezing in liquid nitrogen, the sample was cut and immediately captured on a coverslip, stained with hematoxylin and eosin, and evaluated by image apposition. The area of interest in the original cryopreserved tumor block was then trimmed, and the microdissected sample was transferred to a previously identified tube, which was immediately placed under dry ice.
Prior to initiation, the research here presented was approved by the Research Ethics Committee of the University Hospital of the Faculty of Medicine of University of Sao Paulo, processes number 9375/2003 and 7645/99. The mentioned Committee is in agreement with the Helsinki Declaration requirements for research carried out on humans. Informed consent was also taken from each patient (or their legal representative) involved in this project, also in accordance to the Helsinki Declaration.
RNA extraction and cDNA synthesis
Total cellular RNA was extracted using Trizol® Reagent (Invitrogen, Carlsbad, CA, USA) and RNA was reverse transcribed to single-stranded cDNA using a High Capacity Kit (Applied Biossystems, Foster City, CA, USA) according to the manufacturer's protocol.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Messenger RNA expression level for each HDAC was evaluated using an ABI 7500 machine (Applied Biosystems, Foster City, CA, USA). Amplifications were obtained using on demand TaqMan® probes (Applied Biosystems, Foster City, CA, USA) for each HDAC. For relative quantification of gene expression, standard curves were constructed for each gene by considering at least 3 points in triplicate of 10-fold serial dilution of cDNA in water, starting from 1:10 of a volume of undiluted cDNA transcribed from 1.0 μg of total RNA. The slopes of standard curves ranged from -3.17 to -3.87. Blank and standard controls (calibrators) were run in parallel to verify amplification efficiency within each experiment. To normalize differences in the amount of total cDNA added to each reaction, β-glucuronidase (GUS β) gene expression was used as an endogenous control. As a calibrator sample (reference sample for relative quantification), the U343 cell line was used. To obtain the Ct (cycle) values, we established a threshold of 0.1. All reactions were made in duplicate, and all procedures were carried out at 4°C.
For protein analysis, 30 μg of each sample was loaded and separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis . Proteins were transferred to nitrocellulose membranes, and the membranes were then incubated in 1% Tris-buffered saline Tween-20 (TBST) containing 5% (w/v) dried non-fat milk for 1 hour at room temperature. The primary antibodies were diluted at 1:3000 in TBST containing 5% (w/v) milk: HDAC9 (Abcam, Cambridge, MA), Acetyl-Lys H3 (Abcam, Cambridge, MA), and Acetyl-Lys H4 (Upstate Biotechnology Lake Placid, NY), and the membranes were incubated for 1 hour at room temperature, The membranes were then washed 3 times with TBST, incubated with the secondary antibody (1:5000 in TBST) labeled by horseradish peroxidase (Abcam, Cambridge, MA) for 1 hour at room temperature, and washed 3 times with TBST. The secondary antibody was visualized using electron chemiluminescent reagent (Pierce, Rockford, IL). Films were exposed from 10 to 60 seconds and developed.
Comparison of gene expression between groups of tumor was performed by nonparametric testes Mann-Whitney and Kruskall-Wallis. The level of significance was set at p < 0.05 in all analyses.
Global expression of HDACgenes in gliomas and normal brain tissue
Relative expression (medians) of HDAC genes in different groups of tumor and normal brain tissue.
Astrocytoma grades I and II
Astrocytoma grade III
Comparison of the HDACmRNA levels in low- and high-grade gliomas and normal brain tissue
Statistical comparison (Kruskall-Wallis analysis) of levels of HDAC expression (medians) between low-grade (astrocytomas grade I and II) and high-grade (astrocytomas grade III and glioblastomas) astrocytomas.
Low-grade astrocytomas × high-grade astrocytomas
Seven of 8 class II HDAC genes (exception for HDAC4) were expressed at lower levels in high-grade astrocytomas compared to low-grade astrocytomas (p < 0.05; Table 2). The same significant difference for low-grade and high-grade gliomas was observed for HDAC11 (class IV).
Statistical comparison (Mann-Whitney analysis) of levels of HDAC expression (medians) between tumor groups.
AI and II
AI and II
AI and II
Protein analysis: Acetyl H3 but not Acetyl H4 correlates with mRNA levels
Anti-acetyl histone H3 and anti-acetyl histone H4 antibodies were also used to verify the level of acetylated histones H3 and H4 and to correlate the findings with histone deacetylase activity in the groups studied (Figure 3b).
Considering the large number of HDAC genes with low levels of expression in glioblastomas, we expected that the levels of acetylated histones were higher in those tumors. Interestingly, when we analyzed the acetylation levels of the H3 and H4 histones, H3 histone acetylation, but not H4 histone acetylation, correlated with the data obtained by qRT-PCR (Figure 3B). Glioblastoma samples showed higher levels of acetylated histone H3 than normal brain and low-grade gliomas.
In this study we evaluated and compared mRNA levels of 12 HDAC genes in astrocytomas and normal brain tissue. As mentioned before, the acetylation levels of histones is a process regulated by two groups of important enzymes: HATs and HDACs, and the balance of the activities of these two enzymes is tightly related to the gene expression status in the cell. The regulation of HDACs has been studied, but is not yet well established. The reason for that is maybe because HDACs seem to be regulated at multiple levels including cellular compartmentalization, association with other factors, abundance, activity states and genome-wide distribution.
Considering that altered gene expression is frequently observed in cancer, a relationship between HDACs and cancer progression has been postulated. Wade P.  suggested that loss of targeting of class I HDACs through disruption of a transcriptional corepressor and the inappropriate redistribution of class II resulted in the misregulated gene expression in cancer.
Although a crucial role for HDACs in gene transcription and their possible involvement in cancer has been proposed, no studies have demonstrated the expression profile of 3 classes of HDACs simultaneously in brain tumor.
Our study did not find differential gene expression of class I HDACs in high-grade and low-grade gliomas which may indicate that class of deacetylases seems to not be directly involved with malignancy of gliomas. Only a few studies have evaluated the level of class I HDAC expression in cancer: Huang BH et al.  demonstrated that HDAC1 and HDAC2 seem to be upregulated in colon cancer; Choi JH et al.  demonstrated an overexpression of HDAC1 mRNA 68% of gastric cancer tissues studied by them (17 of 25) and elevated expression of HDAC1 protein was also detected in 61% of the gastric cancer samples (11 of 18). Expression of class I HDAC3 was also shown elevated in astrocytic glial tumors compared to nonmalignant gliosis . On the other hand, Ozdag H. et al.  showed that HDAC1 is significantly lower in colorectal cancer samples in comparison to normal colorectal tissues.
For class II HDACs, downregulation of its expression in glioblastoma compared to low-grade gliomas and normal brain tissue was demonstrated and statistically confirmed in our study, indicating a negative correlation between HDAC expression and malignancy in gliomas. In agreement with our study, some authors have demonstrated downregulation of these deacetylases and their relationship with prognosis in cancer as well. Ozdag H. et al.  showed that HDAC5 and HDAC7 are significantly lower in colorectal cancer samples in comparison to normal colorectal tissues. These authors also showed downregulation of HDAC5 in renal tumors compared to normal renal tissue. Downregulation of HDAC gene expression has also been observed in lung cancer: reduced expression of class II HDAC genes (mostly HDAC10) seems to be significantly associated with poor prognosis, suggesting that class II HDACs may repress critical genes that may have important roles in lung cancer progression . Like in our study, these authors demonstrated that class I HDACs seem to have no correlation with malignancy of those tumors.
The downregulation of HDAC genes in cancer may be difficult to explain, since multiple factors are involved in the regulation of these enzymes. Unlike class I HDACs, which are predominantly localized in the nucleus, class II HDACs actively shuttle between the cytoplasm and nucleus being under control of classic cellular signaling pathways, and cellular localizations represents a fundamental mechanism for them [12, 14]. Additionally, class II HDACs seem to have additional levels of regulation, which makes elucidation of the mechanism of gene transcription regulation more complicated.
Our study seems to reveal the involvement of class II HDACs in glioma malignancy. If we consider that, in general, increased levels of acetylation (downregulation of HDACs) is related to higher transcriptional activity, we could predict that gene transcription in malignant gliomas may be upregulated. In that case we could infer that some proto-oncogenes might be overexpressed and somehow leading to the malignancy. The overexpression of proto-oncogenes in gliomas has been well documented. Besides EGFR, which is found overexpressed in 40% of gliomas, the genes N-MYC, C-MYC, PDGFR-α, MYB, K-RAS, CDK-4 and MDM2 are the most commonly amplified oncogenes in gliomas [33–37]. However, due to the fact that these deacetylases are regulated at several levels, additional information about the functionality of HDACs in gliomas is required.
In order to correlate mRNA and protein levels of HDACs, we analyzed HDAC9 protein levels in all groups of tumors studied. Western blot analysis showed that HDAC9 protein is expressed at a higher concentration in normal brain and low-grade gliomas than in high-grade gliomas, validating the data obtained by real-time PCR.
We also evaluated HDAC activity by analyzing histone acetylation levels in tumor samples and normal brain. When we analyzed the levels of H3 and H4 acetylated histones, we observed an increased level in acetylation of H3 but not of H4 histone in glioblastomas compared to low-grade astrocytomas and normal brain tissue. Considering the low levels of HDAC expression in glioblastomas, it was expected that the levels of acetylated histones should be more elevated in those tumors, as demonstrated here for histone H3. On the other hand, the lack of correlation between low HDAC expression and high histone H4 deacetylation levels in glioblastomas could be explained by the existence of cofactors or unidentified regulators. Some few authors have already demonstrated that the specificity of HDACs depends on cofactors which makes HDAC specificity a complicated process [38–41]. It is tempting to speculate that class II of HDACs could be responsible for deacetylation of histone H3 more than histone H4. However, the data here presented are not enough to infer about the specificity of HDACs in astrocytomas. Moreover, it has been observed that differences between HDAC subtype specificity do not coincide with the division into class I and class II enzymes. HDAC1, HDAC3 (class I), and HDAC6 (class II) seem to be very similar in substrate specificity and mainly differ in the degree of specificity . Until now, a lot of data has been generated about HDAC research, but the natural substrates of different HDACs and their substrate specificities is still not well understood.
The class IV HDAC11 enzyme seems to be an unusual member of the HDAC family. Its sequence is not homologous to any other HDAC, and it may have distinct physiological roles. This enzyme, like members of the class II HDACs is expressed more in brain, heart, skeletal muscle, and kidney . In our study, we also found high levels of HDAC11 in normal brain tissue and significant differential expression was also observed for this enzyme in low-grade and high-grade gliomas. Little is known about this unique HDAC, and its relation to malignancy of gliomas is yet to be elucidated.
Even considering that to evaluate the effect of HDAC inhibitors in gliomas was not the aim of the present study, the finding that most of the HDAC genes are downregulated in glioblastomas could lead us to consider that HDACis may not be effective in the treatment of high-grade gliomas. Some studies have demonstrated radiosensitization of gliomas after HDACi treatment [21, 22]. Therefore, despite the low levels of HDAC gene expression in glioblastomas, HDACis seem to be potential therapeutical targets for glioma treatment. The explanation to this may point to the existence of nonhistone substrates for HDACs. Although histones are the most thoroughly studied as HDAC substrates, several reports have shown that HDACs are also responsible for the deacetylation of diverse types of nonhistone proteins, including transcriptional factors, signal transduction mediators, and molecular chaperones (a summarized table of nonhistone substrates for HDACs can be found in ). Additionally, recent evidences suggest that modulation of gene expression through histone remodeling might not be the only process responsible for the antiproliferative action of HDACis [42, 43]. Although the present study has demonstrated that most of HDACs genes are downregulated in glioblastomas, no experiment was performed in order to analyze the effect of HDAC inhibitors on glioma treatment, therefore the effect of these inhibitors on glioma treatment should be addressed in a separate manuscript.
Our study has established a negative correlation between HDAC gene expression and glioma grade, suggesting that class II and class IV HDACs might play an important role in glioma malignancy. This differential HDAC expression may provide insight into development of novel treatment approaches for this devastating disease. However, a more complete understanding of the biological function and specificity of the diverse HDAC isoforms and their involvement in the cancer process is necessary.
We thank Dr. John F. de Groot and Dr. Vinay Puduvalli from MD Anderson Cancer Center (Houston, Tx, USA) for providing Actin and Acetyl-H4 antibodies, respectively. We also thank Priscila C. Leite for the technical assistance in this work.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007, 114 (2): 97-109. 10.1007/s00401-007-0243-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin HY, Chen CS, Lin SP, Weng JR, Chen CS: Targeting histone deacetylase in cancer therapy. Medicinal research reviews. 2006, 26 (4): 397-413. 10.1002/med.20056.View ArticlePubMedGoogle Scholar
- Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Human molecular genetics. 2001, 10 (7): 693-698. 10.1093/hmg/10.7.693.View ArticlePubMedGoogle Scholar
- Gray SG, Ekstrom TJ: The human histone deacetylase family. Experimental cell research. 2001, 262 (2): 75-83. 10.1006/excr.2000.5080.View ArticlePubMedGoogle Scholar
- Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell research. 2007, 17 (3): 195-211.PubMedGoogle Scholar
- de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical journal. 2003, 370 (Pt 3): 737-749. 10.1042/BJ20021321.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & development. 1999, 13 (15): 1924-1935. 10.1101/gad.13.15.1924.View ArticleGoogle Scholar
- Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of biological chemistry. 2006, 281 (19): 13548-13558. 10.1074/jbc.M510023200.View ArticlePubMedGoogle Scholar
- Grozinger CM, Hassig CA, Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proceedings of the National Academy of Sciences of the United States of America. 1999, 96 (9): 4868-4873. 10.1073/pnas.96.9.4868.View ArticlePubMedPubMed CentralGoogle Scholar
- Verdin E, Dequiedt F, Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19 (5): 286-293. 10.1016/S0168-9525(03)00073-8.View ArticlePubMedGoogle Scholar
- Kao HY, Downes M, Ordentlich P, Evans RM: Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes & development. 2000, 14 (1): 55-66.Google Scholar
- Verdel A, Khochbin S: Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. The Journal of biological chemistry. 1999, 274 (4): 2440-2445. 10.1074/jbc.274.4.2440.View ArticlePubMedGoogle Scholar
- Lemercier C, Verdel A, Galloo B, Curtet S, Brocard MP, Khochbin S: mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. The Journal of biological chemistry. 2000, 275 (20): 15594-15599. 10.1074/jbc.M908437199.View ArticlePubMedGoogle Scholar
- Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T: HDAC4 deacetylase associates with and represses the MEF2 transcription factor. The EMBO journal. 1999, 18 (18): 5099-5107. 10.1093/emboj/18.18.5099.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th'ng J, Han J, Yang XJ: HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol. 1999, 19 (11): 7816-7827.View ArticlePubMedPubMed CentralGoogle Scholar
- Blander G, Guarente L: The Sir2 family of protein deacetylases. Annual review of biochemistry. 2004, 73: 417-435. 10.1146/annurev.biochem.73.011303.073651.View ArticlePubMedGoogle Scholar
- Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000, 403 (6771): 795-800. 10.1038/35001622.View ArticlePubMedGoogle Scholar
- Marmorstein R: Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochemical Society transactions. 2004, 32 (Pt 6): 904-909.View ArticlePubMedGoogle Scholar
- Gao L, Cueto MA, Asselbergs F, Atadja P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of biological chemistry. 2002, 277 (28): 25748-25755. 10.1074/jbc.M111871200.View ArticlePubMedGoogle Scholar
- Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M: Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. International journal of radiation oncology, biology, physics. 2007, 69 (1): 214-220.View ArticlePubMedGoogle Scholar
- Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. International journal of cancer. 2005, 114 (3): 380-386. 10.1002/ijc.20774.View ArticlePubMedGoogle Scholar
- Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA: In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology. 2007, 9 (2): 82-88. 10.1215/15228517-2006-032.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim JH, Shin JH, Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. International journal of radiation oncology, biology, physics. 2004, 59 (4): 1174-1180. 10.1016/j.ijrobp.2004.03.001.View ArticlePubMedGoogle Scholar
- Sawa H, Murakami H, Kumagai M, Nakasato M, Yamauchi S, Matsuyama N, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H: Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta neuropathologica. 2004, 107 (6): 523-531. 10.1007/s00401-004-0841-3.View ArticlePubMedGoogle Scholar
- Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, Carroll RS: Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of neuro-oncology. 2007, 83 (3): 267-275. 10.1007/s11060-007-9337-z.View ArticlePubMedGoogle Scholar
- Wetzel M, Premkumar DR, Arnold B, Pollack IF: Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. Journal of neurosurgery. 2005, 103 (6 Suppl): 549-556.PubMedGoogle Scholar
- Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227 (5259): 680-685. 10.1038/227680a0.View ArticlePubMedGoogle Scholar
- Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell death and differentiation. 2005, 12 (4): 395-404. 10.1038/sj.cdd.4401567.View ArticlePubMedGoogle Scholar
- Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001, 92 (12): 1300-1304.View ArticlePubMedGoogle Scholar
- Liby P, Kostrouchova M, Pohludka M, Yilma P, Hrabal P, Sikora J, Brozova E, Kostrouchova M, Rall JE, Kostrouch Z: Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours. Folia biologica. 2006, 52 (1-2): 21-33.PubMedGoogle Scholar
- Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C: Differential expression of selected histone modifier genes in human solid cancers. BMC genomics. 2006, 7: 90-10.1186/1471-2164-7-90.View ArticlePubMedPubMed CentralGoogle Scholar
- Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International journal of cancer. 2004, 112 (1): 26-32. 10.1002/ijc.20395.View ArticlePubMedGoogle Scholar
- Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP: Cytogenetic and molecular abnormalities in astrocytic gliomas (Review). Oncology reports. 2000, 7 (2): 401-412.PubMedGoogle Scholar
- Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, Aldape K, Sawaya R, Bruner JM, Fuller GN, Zhang W: Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics. 2006, 6 (10): 2964-2971. 10.1002/pmic.200500555.View ArticlePubMedGoogle Scholar
- Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology. 1999, 1 (1): 44-51. 10.1215/15228517-1-1-44.PubMedPubMed CentralGoogle Scholar
- Michotte A, Neyns B, Chaskis C, Sadones J, In 't Veld P: Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta neurologica Belgica. 2004, 104 (4): 148-153.PubMedGoogle Scholar
- Ng HK, Lam PY: The molecular genetics of central nervous system tumors. Pathology. 1998, 30 (2): 196-202. 10.1080/00313029800169236.View ArticlePubMedGoogle Scholar
- Kolle D, Brosch G, Lechner T, Pipal A, Helliger W, Taplick J, Loidl P: Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry. 1999, 38 (21): 6769-6773. 10.1021/bi982702v.View ArticlePubMedGoogle Scholar
- Riester D, Hildmann C, Grunewald S, Beckers T, Schwienhorst A: Factors affecting the substrate specificity of histone deacetylases. Biochemical and biophysical research communications. 2007, 357 (2): 439-445. 10.1016/j.bbrc.2007.03.158.View ArticlePubMedGoogle Scholar
- Wegener D, Hildmann C, Riester D, Schwienhorst A: Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Analytical biochemistry. 2003, 321 (2): 202-208. 10.1016/S0003-2697(03)00426-3.View ArticlePubMedGoogle Scholar
- Wiren M, Silverstein RA, Sinha I, Walfridsson J, Lee HM, Laurenson P, Pillus L, Robyr D, Grunstein M, Ekwall K: Genomewide analysis of nucleosome density histone acetylation and HDAC function in fission yeast. The EMBO journal. 2005, 24 (16): 2906-2918. 10.1038/sj.emboj.7600758.View ArticlePubMedPubMed CentralGoogle Scholar
- Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. The Journal of biological chemistry. 2001, 276 (25): 22491-22499. 10.1074/jbc.M100206200.View ArticlePubMedGoogle Scholar
- Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer cell. 2003, 4 (1): 13-18. 10.1016/S1535-6108(03)00165-X.View ArticlePubMedGoogle Scholar
- Acharya MR, Sparreboom A, Venitz J, Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular pharmacology. 2005, 68 (4): 917-932. 10.1124/mol.105.014167.View ArticlePubMedGoogle Scholar
- Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annual review of pharmacology and toxicology. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/8/243/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.